No Data
No Data
Actinogen Agrees With US FDA on Trials Required for Marketing Approval of Depressive Disorder Drug Candidate; Shares Rise 3%
Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Xanamem: Alzheimer's Breakthrough Set for 2025, 2026
Actinogen Reports Busy 6 Months as Development of Xanamem Molecule Ramps up
Actinogen Medical Ltd: ACW HY25 results Advancing to latestage clinical development
Actinogen Medical Ltd: Actinogen HY2025 financial report and Appendix 4D
151479178 : What are you talking about
hopeful Andy : what have you invested in. now